SEC Filing · 6-K
BioLineRx Ltd.
SEC Filing
Press release in this filing
BioLineRx Announces $3.75 Million Registered Direct Offering and Concurrent Private →Company context
We are a clinical-stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, focused on the advancement of GLIX1, a first-in-class, oral small-molecule therapy targeting the DNA damage response pathway in glioblastoma, or GBM, and other cancers. In September 2025, we entered into a collaboration transaction with Hemispherian AS, a Norwegian biotechnology company specializing in small-molecule cancer therapeutics, to develop, clinically evaluate, and commercialize GLIX1, Hemispherian’s lead drug candidate. Under the terms of the collaboration agreement, development of GLIX1 is being conducted by Tetragon Biosciences Ltd., a newly formed company and our subsidiary, established to advance the program.